Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine-based induction therapy in pediatric acute myeloid leukemia (AML)
2013-000018-39Phase 2Terminated
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of clofarabine in acute myeloid leukemia (AML), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Event-free survival. Started Sep 2014; status: terminated.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2013-000018-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000018-39.